Shop
eStoreRx™
Online Supplement Dispensary
Easy direct-to-patient ordering & fulfilment for Lifelong Wellness, eStoreRx™ is offered as part of the WholePractice membership or as a stand-alone program.
For over 40 years, Biotics Research Corporation has revolutionized the nutritional supplement industry by utilizing “The Best of Science and Nature”. Combining nature’s principles with scientific ingenuity, our products magnify the nutritional
This inclusive membership contains all of the the tools you need to grow your business, including WholeLifeRx™, Nimativ®, WholeLifeQ™, eStoreRx™ and Practice Success Programs.
Easy direct-to-patient ordering & fulfilment for Lifelong Wellness, eStoreRx™ is offered as part of the WholePractice membership or as a stand-alone program.
November 14 2024
Exciting research is being done in the burgeoning field called Metabolic Psychiatry, which is dedicated to addressing the bioenergetic underpinnings o...
When thinking about diabetes and dysmetabolism, we look at a number of tissues such as adipose, liver, muscle and pancreas, but are we considering enough the role of the gut? Metabolic syndrome is defined as a cluster of physiological abnormalities that increase the risk of developing cardiovascular disease and type 2 diabetes. Risk factors include a large waistline, a high triglyceride level, a low HDL cholesterol level, high blood pressure and high fasting blood sugar.
What about increased intestinal permeability?
According to a 2016 study, the gut’s immune system is an important contributor to metabolic disease, and may be a therapeutic target when looking at systemic inflammation in insulin resistance. Altered gut immunity is associated with changes to the gut microbiota, intestinal barrier function, gut-residing immune cells, and oral tolerance to luminal antigens, which may increase the risk for pathogenic infections and, also, drive chronic inflammation.
A recent study entitled, Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection investigated the role of leptin, gut microbiota and obesity as mediators of gut permeability through several mouse models of obesity and diabetes. They found that regardless of leptin or obesity status, all of the mice who displayed increased permeability and persistent infection were hyperglycemic, concluding that “hyperglycemia drives intestinal barrier permeability, through GLUT2-dependent transcriptional reprogramming of intestinal epithelial cells and alteration of tight and adherence junction integrity”.
After extensive association between dysmetabolism and intestinal permeability in rodents, the authors of the study wanted to determine if hyperglycemia influenced gut permeability in humans. Mirroring results in the rodent study, they describe a “mechanistic role for intracellular hyperglycemia in the intestinal epithelia, independent of the microbiome, in driving intestinal permeability”.
In summary, the study makes a pretty convincing case that glucose toxicity impacts the gut, and that intestinal permeability should be included as one more risk factor in metabolic syndrome.
Also, patients with hyperglycemia may benefit from extra gut health support.
Related Biotics Research Products: 
, 
,
Submit this form and you'll receive our latest news and updates.
JAMA Network Open recently published an analysis of several large cohorts of men and women, indicating a lower risk for ...
Learn moreGynecological Endocrinology recently published a systemic review and meta-analysis examining the relationship that glyce...
Learn moreResults of a large population-based observational cohort study examining the association between weight loss and diabete...
Learn more
*These statements have not been evaluated by the Food and Drug Administration. This product has not intended to diagnose, treat, cure, or prevent any disease.
© 2023 Biotics Research Corporation - All Rights Reserved
Submit your comment